Cardiac Biomarkers in Dialysis

Overview

Journal AIMS Genet

Date 2019 Aug 23

PMID 31435501

Citations 8

Authors

Usman Mahmood

David W Johnson

Magid A Fahim

Affiliations

Soon will be listed here.

Abstract

Cardiovascular disease is the major cause of death, accounting for approximately 40 percent of all-cause mortality in patients receiving either hemodialysis or peritoneal dialysis. Cardiovascular risk stratification is an important aspect of managing dialysis patients as it enables early identification of high-risk patients, so therapeutic interventions can be optimized to lower cardiovascular morbidity and mortality. Biomarkers can detect early stages of cardiac injury so timely intervention can be provided. The B-type natriuretic peptides (Brain Natriuretic peptide [BNP] and N-terminal pro-B-type natriuretic peptide [NT-proBNP]) and troponins have been shown to predict mortality in dialysis patients. Suppression of tumorigenicity 2 (ST2) and galectin-3 are new emerging biomarkers in the field of heart failure in both the general and dialysis populations. This article aims to discuss the current evidence regarding cardiac biomarker use to diagnose myocardial injury and monitor the risk of major adverse cardiovascular events in patients undergoing dialysis.

Citing Articles

Triglyceride-glucose index and prognosis in individuals afflicted with heart failure and chronic kidney disease.

Chen Y, Li S, Yang K, Wu B, Xie D, Peng C ESC Heart Fail. 2024; 11(5):3120-3132.

PMID: 38864260 PMC: 11424337. DOI: 10.1002/ehf2.14898.

Cardiac amyloidosis is not a single disease: a multiparametric comparison between the light chain and transthyretin forms.

Neculae G, Adam R, Jercan A, Badelita S, Tjahjadi C, Draghici M ESC Heart Fail. 2024; 11(5):2825-2834.

PMID: 38757395 PMC: 11424370. DOI: 10.1002/ehf2.14852.

Pathophysiological concepts and screening of cardiovascular disease in dialysis patients.

Echefu G, Stowe I, Burka S, Basu-Ray I, Kumbala D Front Nephrol. 2023; 3:1198560.

PMID: 37840653 PMC: 10570458. DOI: 10.3389/fneph.2023.1198560.

Assessment and management of heart failure in patients with chronic kidney disease.

Guaricci A, Sturda F, Russo R, Basile P, Baggiano A, Mushtaq S Heart Fail Rev. 2023; 29(2):379-394.

PMID: 37728751 PMC: 10942934. DOI: 10.1007/s10741-023-10346-x.

Prognostic value of cardiac troponin in dialysis patients with paroxysmal supraventricular tachycardia.

Wang C, Yen C, Chen S, Lo H, Ng C, Chaou C Medicine (Baltimore). 2022; 101(36):e30513.

PMID: 36086794 PMC: 10980411. DOI: 10.1097/MD.0000000000030513.

References

Liang F, Gardner D . Mechanical strain activates BNP gene transcription through a p38/NF-kappaB-dependent mechanism. J Clin Invest. 1999; 104(11):1603-12. PMC: 409860. DOI: 10.1172/JCI7362. View

Troughton R, Frampton C, Yandle T, Espiner E, Nicholls M, Richards A . Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000; 355(9210):1126-30. DOI: 10.1016/s0140-6736(00)02060-2. View

Parfrey P . Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management. Nephrol Dial Transplant. 2000; 15 Suppl 5:58-68. DOI: 10.1093/ndt/15.suppl_5.58. View

Wiese S, Breyer T, Dragu A, Wakili R, Burkard T, Schmidt-Schweda S . Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length. Circulation. 2000; 102(25):3074-9. DOI: 10.1161/01.cir.102.25.3074. View

Clerico A, Caprioli R, Del Ry S, Giannessi D . Clinical relevance of cardiac natriuretic peptides measured by means of competitive and non-competitive immunoassay methods in patients with renal failure on chronic hemodialysis. J Endocrinol Invest. 2001; 24(1):24-30. DOI: 10.1007/BF03343804. View

Mallamaci F, Zoccali C, Tripepi G, Benedetto F, Parlongo S, Cataliotti A . Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int. 2001; 59(4):1559-66. DOI: 10.1046/j.1523-1755.2001.0590041559.x. View

Zoccali C, Mallamaci F, Benedetto F, Tripepi G, Parlongo S, Cataliotti A . Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol. 2001; 12(7):1508-1515. DOI: 10.1681/ASN.V1271508. View

Fredericks S, Chang R, Gregson H, Bewick M, Collinson P, Gaze D . Circulating cardiac troponin-T in patients before and after renal transplantation. Clin Chim Acta. 2001; 310(2):199-203. DOI: 10.1016/s0009-8981(01)00547-2. View

Ellis K, Dreisbach A, Lertora J . Plasma elimination of cardiac troponin I in end-stage renal disease. South Med J. 2001; 94(10):993-6. View

10.

Morrow D, Cannon C, Rifai N, Frey M, Vicari R, Lakkis N . Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA. 2001; 286(19):2405-12. DOI: 10.1001/jama.286.19.2405. View

11.

Ruilope L, van Veldhuisen D, Ritz E, Luscher T . Renal function: the Cinderella of cardiovascular risk profile. J Am Coll Cardiol. 2001; 38(7):1782-7. DOI: 10.1016/s0735-1097(01)01627-8. View

12.

Zoccali C, Mallamaci F, Tripepi G, Benedetto F, Cutrupi S, Parlongo S . Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol. 2001; 13(1):134-141. DOI: 10.1681/ASN.V131134. View

13.

Longenecker J, Coresh J, Powe N, Levey A, Fink N, Martin A . Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol. 2002; 13(7):1918-27. DOI: 10.1097/01.asn.0000019641.41496.1e. View

14.

Maisel A, Krishnaswamy P, Nowak R, McCord J, Hollander J, Duc P . Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002; 347(3):161-7. DOI: 10.1056/NEJMoa020233. View

15.

McCullough P, Nowak R, McCord J, Hollander J, Herrmann H, Steg P . B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation. 2002; 106(4):416-22. DOI: 10.1161/01.cir.0000025242.79963.4c. View

16.

Goto T, Takase H, Toriyama T, Sugiura T, Kurita Y, Tsuru N . Increased circulating levels of natriuretic peptides predict future cardiac event in patients with chronic hemodialysis. Nephron. 2002; 92(3):610-5. DOI: 10.1159/000064100. View

17.

Weinberg E, Shimpo M, De Keulenaer G, Macgillivray C, Tominaga S, Solomon S . Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002; 106(23):2961-6. PMC: 1460012. DOI: 10.1161/01.cir.0000038705.69871.d9. View

18.

Zoccali C, Mallamaci F, Panuccio V, Tripepi G, Cutrupi S, Parlongo S . Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney Int Suppl. 2003; (84):S98-102. DOI: 10.1046/j.1523-1755.63.s84.49.x. View

19.

Lee S, Song J, Kim G, Lim H, Kim M . Plasma brain natriuretic peptide concentration on assessment of hydration status in hemodialysis patient. Am J Kidney Dis. 2003; 41(6):1257-66. DOI: 10.1016/s0272-6386(03)00358-5. View

20.

Fagugli R, Palumbo B, Ricciardi D, Pasini P, Santirosi P, Vecchi L . Association between brain natriuretic peptide and extracellular water in hemodialysis patients. Nephron Clin Pract. 2003; 95(2):c60-6. DOI: 10.1159/000073669. View